Just the Facts on Altimmune, Inc. (ALT)

Altimmune, Inc. (ALT) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $0.58, up from yesterday’s close by 7.87%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Altimmune, Inc. (ALT) currently trades with a market capitalization of $14.53 Million. That value represents a market adjusting for revenues that have been growing by 159.06 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $ over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of -$0.5 on a per share basis this quarter. Perhaps, that suggests something about why 22.75% of the outstanding share supply is held by institutional investors.

Technical Analysis

Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stock’s movement on the chart, Altimmune, Inc. recorded a 52-week high of $5.37. It is now trading 4.79% off that level. The stock is trading $1.03 its 50-day moving average by 0.45%. The stock carved out a 52-week low down at $0.48.

In recent action, Altimmune, Inc. (ALT) has made a move of -25.64% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 14.61, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 5.94% with $13.10 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ALT.

Previous articleThe Case for and Against Zayo Group Holdings, Inc. (ZAYO)
Next articleTaking a Look at the Data Behind Sangamo Therapeutics, Inc. (SGMO)